PMID- 34044609 OWN - NLM STAT- MEDLINE DCOM- 20210811 LR - 20210811 IS - 1557-8534 (Electronic) IS - 1547-3287 (Linking) VI - 30 IP - 15 DP - 2021 Aug 1 TI - Human Umbilical Cord Mesenchymal Stromal Cell Treatment of Severe COVID-19 Patients: A 3-Month Follow-Up Study Following Hospital Discharge. PG - 773-781 LID - 10.1089/scd.2021.0015 [doi] AB - Previously, we demonstrated the therapeutic effects of human umbilical cord mesenchymal stromal cells (hUC-MSCs) in severe coronavirus disease 2019 (COVID-19) patients. In this 3-month follow-up study, we examined discharged patients who had received hUC-MSC therapy to assess the safety of this therapy and the health-related quality of life (HRQL) of these patients. The follow-up cohort consisted of 28 discharged severe COVID-19 patients who received either the standard treatment (the control group) or the standard treatment plus hUC-MSC therapy. We examined liver function, kidney function, pulmonary function, coagulation, tumor markers, and vision. We also conducted electrocardiography (ECG) analysis, let the patients answer the St. George's Respiratory Questionnaire (SGRQ), and performed computed tomography (CT) imaging for assessing the lung changes. No obvious adverse effects were observed in the hUC-MSC group after 3 months. Measurements of blood routine index, C-reactive protein and procalcitonin, liver and kidney function, coagulation, ECG, tumor markers, and vision were almost within the normal ranges in both the treatment and control groups. Forced expiratory volumes in 1 s (FEV1) (% of predicted) were 71.88% +/- 8.46% and 59.45% +/- 27.45% in the hUC-MSC and control groups (P < 0.01), respectively, and FEV1/forced vital capacity (FEV1/FVC) ratios were 79.95% +/- 8.00% and 58.97% +/- 19.16% in the hUC-MSC and control groups, respectively (P < 0.05). SGRQ scores were lower in the hUC-MSC group than in the control group (15.25 +/- 3.69 vs. 31.9 +/- 8.78, P < 0.05). The rate of wheezing in the hUC-MSC group was also significantly lower than that in the control group (37.5% vs. 75%, P < 0.05). There were no significant differences in CT scores between the two groups (0.60 +/- 0.88 vs. 1.00 +/- 1.31, P = 0.917). Overall, the intravenous transplantation of hUC-MSCs accelerated partial pulmonary function recovery and improved HRQL, indicating relative safety and preliminary efficacy of this treatment for patients with severe COVID-19. FAU - Feng, Ganzhu AU - Feng G AD - Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Shi, Lei AU - Shi L AD - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China. FAU - Huang, Tingrong AU - Huang T AD - Department of Nephrology, Huangshi Hospital of Traditional Chinese Medicine, Huangshi, China. FAU - Ji, Ningfei AU - Ji N AD - Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Zheng, You AU - Zheng Y AD - Department of Nephrology, Huangshi Hospital of Traditional Chinese Medicine, Huangshi, China. FAU - Lin, Huan AU - Lin H AD - Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Niu, Changming AU - Niu C AD - Department of Critical Care Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Wang, Yan AU - Wang Y AD - Jiangsu Cell Tech Medical Research Institute, Nanjing, China. FAU - Li, Ruyou AU - Li R AD - Department of Nephrology, Huangshi Hospital of Traditional Chinese Medicine, Huangshi, China. FAU - Huang, Mao AU - Huang M AD - Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. FAU - Chen, Xiaolin AU - Chen X AD - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China. FAU - Shu, Lei AU - Shu L AD - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China. FAU - Wu, Mingjing AU - Wu M AD - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China. FAU - Deng, Kaili AU - Deng K AD - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China. FAU - Wei, Jing AU - Wei J AD - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China. FAU - Wang, Xueli AU - Wang X AD - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China. FAU - Cao, Yang AU - Cao Y AD - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China. FAU - Yan, Jiaxin AU - Yan J AD - Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210629 PL - United States TA - Stem Cells Dev JT - Stem cells and development JID - 101197107 SB - IM MH - Adult MH - Aged MH - COVID-19/epidemiology/pathology/*therapy MH - Case-Control Studies MH - China/epidemiology MH - Cohort Studies MH - Comorbidity MH - *Cord Blood Stem Cell Transplantation/statistics & numerical data MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - *Mesenchymal Stem Cell Transplantation/statistics & numerical data MH - Middle Aged MH - Patient Discharge MH - Respiratory Function Tests MH - SARS-CoV-2/physiology MH - Severity of Illness Index MH - Treatment Outcome MH - Umbilical Cord/cytology OTO - NOTNLM OT - FEV1 OT - FEV1/FVC OT - computed tomography imaging OT - coronavirus disease-2019 OT - human umbilical cord mesenchymal stromal cells OT - pulmonary function EDAT- 2021/05/29 06:00 MHDA- 2021/08/12 06:00 CRDT- 2021/05/28 05:38 PHST- 2021/05/29 06:00 [pubmed] PHST- 2021/08/12 06:00 [medline] PHST- 2021/05/28 05:38 [entrez] AID - 10.1089/scd.2021.0015 [doi] PST - ppublish SO - Stem Cells Dev. 2021 Aug 1;30(15):773-781. doi: 10.1089/scd.2021.0015. Epub 2021 Jun 29.